Studying slime. by Potera, C
M icrobiologists have traditionally
based their knowledge of bacte-
ria on the behavior of colonies
grown from a single species in laboratory
culture plates. These so-called "planktonic"
or free-floating specimens have been used
to determine how well antibiotics and dis-
infectants kill bacteria. In nature, however,
99% of bacteria aggregate as biofilms
complex colonies composed of billions of
bacteria that pool their resources to resist
being killed by antimicrobial agents.
"Microbiologists have been barking up the
wrong tree since the time of Pasteur," says
William Costerton, a microbiologist and
director of the Center for Biofilm
Engineering (CBE) at Montana State
University in Bozeman.
Biofilms, more commonly called slime,
can corrupt any solid surface. The best
known and most studied biofilm is dental
plaque, which secretes acids that destroy
teeth and gums. Biofilms also contaminate
contact lenses, intrauterine devices,
catheters, pacemakers, artificial hearts,
joint implants, and proctoscopes. The
resulting infections often defy high doses
of antibiotics, making it necessary in some
cases to surgically remove an artificial hip
or pacemaker. In the drug industry,
biofilms foul manufacturing tanks. In
1994, several people with asthma died after
inhaling a biofilm that had tainted a com-
pany's therapeutic inhaler. Legionnaire's
disease spreads as an airborne biofilm, and
biofilms clog the lungs of many cystic
fibrosis patients. New evidence suggests
that biofilms may also be the culprit
behind chronic ear infections.
Biofilms wreak havoc in industrial set-
tings, corroding everything from water
pipes to computer chips. Some bacteria in
biofilms convert sulfur to hydrogen sul-
fide, which burns holes in metals and con-
crete. Biofilms also plug pipes, interfering
with heating and cooling systems. Once an
industrial water supply becomes infected
with a biofilm, seemingly pure water can
befoul the computer chips or artificial
limbs that it was intended to cleanse. In
addition to the direct problems they cause,
biofilms can also damage the environment
indirectly due to the toxicity ofthe chemi-
cals used to clean them up and keep them
from coming back.
Studying Slime
Before the 1980s, biofilms were the
province of a few microbiologists studying
slime in water and industrial engineers
plagued by biofilms corroding and block-
ing water systems. William Characklis, an
engineering professor at Montana State
University, recognized the need to bring
engineers and microbiologists together to
share their specialized knowledge of
biofilms. Characklis set a personal example
by cross-training himself in microbiology,
attending meetings of both camps, and
teaching diverse graduate students. In
1990, Characklis won National Science
Foundation support to establish the Center
for Microbial Interfacial Process
Engineering at Montana State University,
which drew students and faculty from
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engineering, science, mathematics, and
agricultural disciplines (the center gained
its current name in the mid-1990s).
Understanding and taming biofilms is the
chiefgoal ofthe CBE.
A new breakthrough has identified how
bacteria "talk" to each other when building
a biofilm. A team led by CBE microbiolo-
gist David Davies reported in the 10 April
1998 issue of Science that Pseudomonas
aeruginosa bacteria communicate with each
other through chemical signals called
homoserine lactones (HSLs) when forming
biofilms. Biofilms of P. aeruginosa pose
particular environmental health concerns,
because they are the primary cause ofhos-
pital-acquired infection and the chief bac-
terial species growing in the lungs ofcystic
fibrosis patients. Knowing that HSLs can
modify biofilm development "means we
have one key to turn off the development
of biofilms," says Davies. Potential drugs
that block HSLs have been created and
shown in preliminary trials to block
biofilm formation. At least 40 other types
of bacteria produce HSLs, suggesting that
the natural messenger is widespread among
microbes.
The means of halting HSL-dependent
biofilm communication are just starting to
be understood. One goal is to block the
key bacteria responsible for periodontal
disease. An HSL analog that disrupts the
first stages of biofilm formation on teeth
could be added to toothpaste or mouth-
wash as a prophylactic ingredient, proposes
Costerton. Molecular geneticist John
Geiger, group leader for biotechnology at
the Olin Corporation, a manufacturer of
industrial biocides in Cheshire,
Connecticut, says the HSL findings offer a
new, environmentally benign way to dis-
rupt biofilms. For example, paint used to
prevent biofilm fouling on boats currently
contains toxic heavy metals, which could
be replaced by safer HSL analogs.
Industrial water systems, a prime location
for biofilm contamination, could be made
slime-free by adding analogs that block
biofilm congregation. Such analogs might
be safer and healthier than the chlorine
currently used to kill biofilms in water.
Traditional efforts to kill bacteria have
spawned problems such as antibiotic-resis-
tant strains. "Now we can't even kill
them," says Costerton. "But perhaps we
can coexist with bacteria and manipulate
their bothersome ways.'
Medical Advances
Until recently, microbiologists and indus-
trial engineers assumed that biofilm bacte-
ria behaved like their planktonic counter-
parts. Early microscopic studies ofbiofilms
used dead, stained cells in which the
biofilm structure had been destroyed. In
the early 1990s, the technique of confocal
scanning laser microscopy, which magnifies
live cells in real time without destroying
them, revolutionized ideas about biofilms.
Using this technique, researchers found
that biofilms are highly organized struc-
tures that resemble mushrooms, surround-
edbycirculating water channels thatsupply
nutrients and remove wastes. A biofilm can
contain a single species ofbacteria or sever-
al species living synergistically. Any bacteria
can transform itself into a biofilm once it
attaches to a hard surface in a moist envi-
ronment. Genetic studies confirm that bac-
teria switch on different genes, depending
on whether they're living as free-floating
microbes orclustering as biofilms.
Biofilms secrete a sticky carbohydrate
coating to protect themselves from antibi-
otics and disinfectants. Moreover, up to
40% of the proteins in cell walls differ
between planktonic and biofilm forms of
bacteria as a result ofdifferent gene expres-
sion. So cell targets for traditional antibi-
otics may not be present in biofilm bacte-
ria, making biofilms notoriously difficult
to kill. "The rule of thumb is that 1,500
times more of an antimicrobial agent is
needed to kill a biofilm than a planktonic
bacteria," says Costerton.
Microbiologist Garth Ehrlich, director
ofthe Center for Genomic Sciences at the
Allegheny University of the Health
Sciences in Pittsburgh, Pennsylvania, con-
ducted a study on ear fluid from children
with a condition called otitis media with
effusion (OME), or the persistence offluid
in the middle ear. OME leads to hearing
loss and developmental problems in speech
and socialization. Erlich discovered that
the fluid contained genetic material from
bacteria weeks after antibiotic treatment.
When he analyzed ear fluid from 82 pedi-
atric patients with chronic OME, Ehrlich
found that 35% were positive for
Haemophilus influenzae, thepathogen most
commonly cultured from effusions.
Ehrlich theorized in the 28 January 1998
issue of the Journal ofthe American
MedicalAssociation that H. influenzae per-
sists in the ears of OME patients despite
antibiotic treatment because it's a biofilm.
Now Ehrlich is analyzing gene expres-
sion in samples of ear fluid from OME
patients and comparing it with genes
expressed in free-floating H. influenzae.
Preliminary data reveal marked differences
in gene expression. "In the natural ear envi-
ronment, biofilms appear to be the pre-
dominant mode ofgrowth," says Ehrlich.
Genes unique to the biofilm state will be
identified as possible targets for better
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antibiotics, or genes expressed only in the
biofilm could form the basis ofa new vac-
cine to eliminate the occurrence of ear
infections and the resulting need for antibi-
otics. Ehrlich also suspects that other long-
term infections that are not killed by
antibiotics, such as chronic sinusitis, arise
from biofilms. "OME will serve as a model
for investigating the development ofantibi-
otic resistance in chronic infections and the
demonstration of biofilm communities in
vivo," he says.
Preemptive Strikes
Because biofilm infections are tenacious,
other research is aimed at preventing
biofilms from taking hold. Rabih
Darouiche, an infectious disease specialist
at the Baylor College ofMedicine and the
Veterans Affairs Medical Center, both in
Houston, Texas, helped to develop special
catheters coated with the antibiotics
rifampin and minocycline that were placed
in patients for a variety of medical thera-
pies. "The antibiotic coating cuts down on
clinical infections," says Darouiche, whose
research in this area was published in the
15 August 1997 issue of the Annals of
Internal Medicine. Moreover, in a multi-
center trial, a scanning electron microscope
was used to examine biofilm growth on
catheters inserted for 2 weeks. Mild to
heavy biofilm colonies formed on 35% of
the coated catheters, compared to 80% of
the untreated catheters. The results, pub-
lished in the February 1998 issue of
Critical Care Medicine, support clinical
observations of fewer bloodstream infec-
tions in patients treated with coated
catheters. The antibiotic-coated catheters
received FDA approval in 1996 and are
gradually catching on, says Darouiche.
Neither an electrical current nor antibi-
otics alone will kill biofilms entrenched on
the hard surfaces of medical devices. But
for biofilms already attached to such sur-
faces, Costerton discovered that shocking
them with a small electrical current (15
milliamperes) speeds up the penetration of
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the antibiotics that actually kill them.
Costerton has received a patent on the
electrically based method; prototypes of
various sterilizers have been built for clean-
ing medical devices ranging from contact
lenses to proctoscopes, but none are
advanced enough for marketing.
In looking for ways to prevent biofilm
infections in the urogenital tract, microbi-
ologist Gregor Reid of the University of
Western Ontario in London discovered a
new twist-"good" biofilms. Fifty to 100
species of bacteria populate the urogenital
tracts of healthy women, mostly as
biofilms. Urinary tract infections disrupt
the healthy biofilm population. Reid found
that certain strains of lactobacillus main-
tain and restore the healthy biofilms, and
help prevent urinary tract infections.
When 55 women prone to recurrent uri-
nary tract infections tested an experimental
lactobacillus vaginal suppository weekly for
a year, their infection rate dropped from
6.0 to 1.6 recurrences per patient per year
(International Dairy Journal, in press).
Women want to buy the suppositories, but
"we're having problems finding a corporate
partner," says Reid. "The biopharmaceuti-
cal industry isn't ready for biological pre-
ventive therapy."
Biofilms have risen from scientific
obscurity to become a topic of grant
requests. At the National Institutes of
Health, 8 of 23 institutes are sponsoring
programs and seeking proposals for biofilm
research in areas ranging from the role of
biofilms in ear, urinary, and other infec-
tions to making better biomaterials that
will resist the growth of biofilms. To
Costerton, this means that health officials
are conceding that "a great many medical
problems are caused by biofilms." With
luck, the new research will lead to better
and saferways to control biofilms.
Carol Potera
atswoo e onmne eit
asS
A 606 Volume 106, Number 12, December 1998 * Environmental Health Perspectives